| General Information | |
|---|---|
| ZINC ID | ZINC000045339957 |
| Molecular Weight (Da) | 479 |
| SMILES | N#CCc1c(C(=O)NCc2ccc(F)cc2)nn(-c2ccccc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C25Cl2F1N4O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 128.861 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 33 |
| LogP | 6.201 |
| Activity (Ki) in nM | 2.0893 |
| Polar Surface Area (PSA) | 70.71 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.13 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 23 |
| Fraction csp3 | 0.08 |
| Ilogp | 4.18 |
| Xlogp3 | 5.67 |
| Wlogp | 6.25 |
| Mlogp | 4.49 |
| Silicos-it log p | 6.17 |
| Consensus log p | 5.35 |
| Esol log s | -6.44 |
| Esol solubility (mg/ml) | 0.000175 |
| Esol solubility (mol/l) | 0.00000036 |
| Esol class | Poorly sol |
| Ali log s | -6.92 |
| Ali solubility (mg/ml) | 0.0000576 |
| Ali solubility (mol/l) | 0.00000012 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.21 |
| Silicos-it solubility (mg/ml) | 2.94E-08 |
| Silicos-it solubility (mol/l) | 6.12E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.2 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.26 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.724 |
| Logd | 4.458 |
| Logp | 5.193 |
| F (20%) | 0.001 |
| F (30%) | 0.001 |
| Mdck | - |
| Ppb | 98.50% |
| Vdss | 0.844 |
| Fu | 0.97% |
| Cyp1a2-inh | 0.417 |
| Cyp1a2-sub | 0.138 |
| Cyp2c19-inh | 0.913 |
| Cyp2c19-sub | 0.065 |
| Cl | 4.663 |
| T12 | 0.038 |
| H-ht | 0.294 |
| Dili | 0.97 |
| Roa | 0.661 |
| Fdamdd | 0.852 |
| Skinsen | 0.032 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.561 |
| Bcf | 2.052 |
| Igc50 | 4.91 |
| Lc50 | 6.654 |
| Lc50dm | 6.444 |
| Nr-ar | 0.012 |
| Nr-ar-lbd | 0.323 |
| Nr-ahr | 0.729 |
| Nr-aromatase | 0.925 |
| Nr-er | 0.479 |
| Nr-er-lbd | 0.014 |
| Nr-ppar-gamma | 0.814 |
| Sr-are | 0.764 |
| Sr-atad5 | 0.03 |
| Sr-hse | 0.352 |
| Sr-mmp | 0.861 |
| Sr-p53 | 0.911 |
| Vol | 459.087 |
| Dense | 1.041 |
| Flex | 0.28 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.37 |
| Synth | 2.382 |
| Fsp3 | 0.08 |
| Mce-18 | 23 |
| Natural product-likeness | -1.699 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |